The main Phase 3 dose steps include 2mg, 4mg, 6mg, 9mg and 12mg, with 12mg being the highest dose currently studied in major obesity trials
October 2025
Yes, variants in the GLP1R gene (e.g., rs6923761) have been associated with differences in weight loss response to GLP-1 medications in clinical studies
Dehydration raises nausea risk and can cause other issues, so make fluids a priority
[1] [2] These results should be interpreted in context: they reflect specific dose groups within obesity cohorts and may not apply across all doses, populations, or indications such as type 2 diabetes
Functional and Clinical Relevance of Novel and Known PCSK1 Variants for Childhood Obesity and Glucose Metabolism. Molecular Metabolism, vol